- Home
- BIIB vs CFG Comparison
BIIB vs CFG Comparison
Compare BIIB & CFG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- CFG
- Stock Information
- Founded
- BIIB 1978
- CFG 1828
- Country
- BIIB United States
- CFG United States
- Employees
- BIIB N/A
- CFG N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- CFG Major Banks
- Sector
- BIIB Health Care
- CFG Finance
- Exchange
- BIIB Nasdaq
- CFG Nasdaq
- Market Cap
- BIIB 19.9B
- CFG 21.3B
- IPO Year
- BIIB 1991
- CFG 2014
- Fundamental
- Price
- BIIB $124.40
- CFG $34.05
- Analyst Decision
- BIIB Buy
- CFG Buy
- Analyst Count
- BIIB 27
- CFG 19
- Target Price
- BIIB $220.50
- CFG $49.11
- AVG Volume (30 Days)
- BIIB 1.8M
- CFG 5.2M
- Earning Date
- BIIB 04-23-2025
- CFG 04-16-2025
- Dividend Yield
- BIIB N/A
- CFG 4.64%
- EPS Growth
- BIIB 40.28
- CFG N/A
- EPS
- BIIB 11.18
- CFG 3.03
- Revenue
- BIIB $9,675,900,000.00
- CFG $7,122,000,000.00
- Revenue This Year
- BIIB N/A
- CFG $16.12
- Revenue Next Year
- BIIB N/A
- CFG $8.55
- P/E Ratio
- BIIB $11.75
- CFG $11.95
- Revenue Growth
- BIIB N/A
- CFG N/A
- 52 Week Low
- BIIB $128.51
- CFG $32.06
- 52 Week High
- BIIB $238.00
- CFG $49.25
- Technical
- Relative Strength Index (RSI)
- BIIB 32.01
- CFG 23.80
- Support Level
- BIIB $128.75
- CFG $39.57
- Resistance Level
- BIIB $144.07
- CFG $41.68
- Average True Range (ATR)
- BIIB 3.72
- CFG 1.24
- MACD
- BIIB -1.21
- CFG -0.45
- Stochastic Oscillator
- BIIB 11.38
- CFG 3.14
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About CFG Citizens Financial Group Inc.
Citizens Financial Group is a bank holding company headquartered in Providence, Rhode Island. Its two primary business segments are consumer banking and commercial banking. Citizens offers a mix of retail and commercial products including capital markets and wealth options. The bank has over 1,100 branches in 14 states, although it is concentrated in the Northeast. It has over $220 billion of total assets. It generates maximum revenue from Consumer Banking Segment.